Day 1 - Friday, 26 November 2021
|
|
Time
|
Title
|
Speakers
|
|
3pm - 3.05pm
|
Opening Remarks
|
Dr. Ussama Al Homsi
Deputy Medical Director, Education, Quality and Research, National Centre for Cancer Care and Research Hamad Medical Corporation, Qatar
|
|
3.05pm - 3.25pm
|
Session 1: Care Delivery and Regulatory Policy:
Outcomes of COVID-19 in Cancer Patients: Report from the National COVID Cohort Collaborative (N3C)
|
Dr. Ussama Al Homsi
Deputy Medical Director, Education, Quality and Research, National Centre for Cancer Care and Research Hamad Medical Corporation, Qatar
|
|
3.25pm - 3.45pm
|
Session 2: Breast Advanced: Trastuzumab plus endocrine therapy or chemotherapy as first-line treatment for metastatic breast cancer with hormone receptor-positive and HER2-positive: The sysucc-002 randomized clinical trial
|
Dr. Francois Calaud
Sr. Consultant Medical Oncologist, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar
|
|
3.45pm - 4.05pm
|
Session 3: Breast advanced: Dalpiciclib versus placebo plus fulvestrant in HR+/HER2- advanced breast cancer that relapsed or progressed on previous endocrine therapy (DAWNA-1): A multicenter, randomized, phase 3 study.
|
Dr. Mufid El Mistiri
Sr. Consultant Medical Oncologist, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar
|
|
4.05pm - 4.25pm
|
Session 4: Breast Early: De-escalated neoadjuvant pertuzumab+trastuzumab with or without paclitaxel weekly in HR-/HER2+ early breast cancer: ADAPT-HR-/HER2+ biomarker and survival results
|
Dr. Salha Bujassoum
Director of Medical Oncology,
National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar
|
|
4.25pm - 5pm
|
Break
|
|
5pm - 5.20pm
|
Session 5: Gynae – Oncology: Optimal treatment duration of bevacizumab (BEV) combined with carboplatin and paclitaxel in patients (pts) with primary epithelial ovarian (EOC), fallopian tube (FTC) or peritoneal cancer (PPC): A multicenter open-label randomized 2-arm phase 3 ENGOT/GCIG trial of the AGO Study Group, GINECO, and NSGO (AGO-OVAR 17/BOOST, GINECO OV118, ENGOT Ov-15, NCT01462890).
|
Dr. Hind EL Malik
Sr. Consultant Medical Oncologist, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.
|
|
5.20pm - 5.40pm
|
Session 6: Gynae – Oncology: Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-agnostic ovarian cancer: Final analysis
|
Dr. Hind EL Malik
Sr. Consultant Medical Oncologist, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar
|
|
5.40pm - 6pm
|
Session7: Symptoms and Survivorship: The effects of geriatric assessment on oncologist-patient communication regarding functional status and physical performance in older adults with cancer: A secondary analysis of a 541-subject nationwide URCC NCORP (NCI Community Oncology Research Program) cluster randomized trial.
|
Dr. Azza Adel Hassan
Chief of Palliative Medicine and Fellowship Director of Hospice and Palliative Medicine at the National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.
|
|
6pm - 6.10pm
|
Break
|
|
6.10pm - 6.30pm
|
Session 8: Supportive Care-Low Cost, High Value:
Preventing and Managing Neurology Complication of Therapy. *
|
Dr. Ayman Allam
Sr. Consultant Medical Oncologist, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.
|
|
6.30pm - 6.50pm
|
Session 9: Lung Cancer: Stereotactic ablative radiotherapy in operable stage I NSCLC patients: Long-term results of the expanded STARS clinical trial *
|
Dr. Mohamed Riyas
MD, Consultant Radiation Oncologist, National center for cancer care and research, Hamad Medical Corporation, Qatar
|
|
6.50pm - 7.10pm
|
Session 10: Lung Cancer: Non-small Cell Local-regional/Small Cell/Other - Phase 3 comparison of high-dose once-daily (QD) thoracic radiotherapy (TRT) with standard twice-daily (BID) TRT in limited stage small cell lung cancer (LSCLC): CALGB 30610 (Alliance)/RTOG 0538
|
Dr. Saju Divakar
Consultant Radiation Oncologist, National center for cancer care and research, Hamad Medical Corporation, Qatar
|
|
7.10pm - 7.30pm
|
Session 11: Lung Cancer: First line nivolumab (NIVO) plus ipilimumab (IPI) plus two cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients with advanced non-small cell lung cancer (NSCLC): Two-year update from CheckMate 9LA
|
Dr. Reyad Hassan Mohsen
Sr. Consultant Medical Oncologist, National Center for Cancer Care and Research, Hamad Medical Corporation, Qatar
|
|
7.30pm - 7.50pm
|
Session 12: Lung Cancer: Video-assisted thoracoscopic versus open lobectomy in patients with early-stage lung cancer: One-year results from a randomized controlled trial (VIOLET).
|
Dr. Ehab Massad Sr. Consultant Cardiothoracic Surgeon, Heart Hospital, Hamad Medical Corporation, Qatar.
|
|
7.50pm - 8pm
|
Closing Remarks
|
Dr. Ussama Al Homsi
Deputy Medical Director, Education, Quality and Research, National Centre for Cancer Care and Research. Hamad Medical Corporation, Qatar.
|
